Treatment of post-operative inflammation after cataract extraction with Bromfenac sodium

A cataract is opacity of the lens of the eye that causes partial or total blindness. Cataract formation typically is bilateral, although it is often asymmetrical. Most cases of cataract occur in patients over age 60 or in younger individuals who have risk factors such as diabetes mellitus systemic steroid use, or a history of significant eye trauma. The only treatment for cataract is to surgically remove the opacified lens from the eye to restore transparency of the visual axis.
Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Bromfenac 0.09% ophthalmic solution is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. Potential off-label uses include ocular allergy and reduction of post-cataract cystoid macular edema (CME).    details >>